MetaVia Inc. filed a Form 8-K on November 17, 2026, disclosing that the last patient has completed the final study visit for the company's Phase 1 clinical trial evaluating DA-1726, a novel GLP-1/glucagon dual-receptor agonist.
Key Highlights
- Trial milestone: The last patient has completed the final study visit for the Phase 1 clinical trial of DA-1726, according to the filing.
- Drug candidate: DA-1726 is described in the filing as "a novel GLP-1 (GLP1R)/glucagon (GCGR) dual-receptor agonist."
- Disclosure mechanism: The announcement was made via a press release dated November 17, 2026, attached as Exhibit 99.1.
- Regulatory classification: The information was furnished under Item 7.01 (Regulation FD) and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
- Signed by: Hyung Heon Kim, President and Chief Executive Officer of MetaVia Inc.
MetaVia Reports Last Patient Completes Phase 1 Visit for DA-1726
MetaVia Inc. (NASDAQ:MTVA), headquartered at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts, reported on November 17, 2026, that the last patient has completed the final study visit for its Phase 1 clinical trial of DA-1726. According to the filing, DA-1726 is characterized as "a novel GLP-1 (GLP1R)/glucagon (GCGR) dual-receptor agonist." The company made this disclosure through a press release incorporated by reference into the Current Report as Exhibit 99.1.
The filing was submitted under Item 7.01, Regulation FD Disclosures. The company noted that the information furnished under Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." The company also stated that "the Company's submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD."
The filing includes a forward-looking statements notice, stating that such statements "are based on current expectations and are not guarantees of future performance" and that "actual events or results may differ materially from those in the forward-looking statements." These are the company's own characterizations and are subject to its cautionary language as outlined in Exhibit 99.1 and other regulatory filings.
What Was Disclosed
MetaVia Inc. disclosed via an 8-K filed November 17, 2026, that the last patient completed the final study visit in the Phase 1 trial of DA-1726, a GLP-1/glucagon dual-receptor agonist. The press release was furnished as Exhibit 99.1 under Regulation FD.




Please wait processing your request...